The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase

Stroke

Volumn 36, Issue 1, 2005, Pages 66-73

  Hacke, Werner ^a   Albers, Greg ⁱ   Al Rawi, Yasir ^b   Bogousslavsky, Julien ^d   Davalos, Antonio ^e   Eliasziw, Michael ^f   Fischer, Michael ^c   Furlan, Anthony ^j   Kaste, Markku ^g   Lees, Kennedy R ^h   Soehngen, Mariola ^b   Warach, Steven ^k  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PAION Deutschland GmbH   (Germany)

^c ClinResearch GmbH   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f UNIVERSITY OF CALGARY   (Canada)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h WESTERN INFIRMARY   (United Kingdom)

ⁱ Stanford California and Cofounder   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

more..

Author keywords

Desmoteplase; Magnetic resonance imaging; Stroke; Thrombolytic therapy

Indexed keywords

DESMOTEPLASE; PLACEBO;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HUMAN; MALE; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIFFUSION MAGNETIC RESONANCE IMAGING; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PLASMINOGEN ACTIVATORS; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 19944426190     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000149938.08731.2c     Document Type: Article

References (13)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S; for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomised controlled trial. JAMA. 1999;282:2019-2026.
3. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, Hennerici M; for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P; for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
5. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Gratta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363: 768-774.
6. Reddrop C, Moldrich RX, Beart PM, Liberatore GT, Howells DW, Schleuning WD, Medcalf RL. NMDA-mediated neurotoxicity is potentiated by intravenous tissue-type-, but no vampire bat-plasminogen activator, and is enhanced by fibrin. Stroke. In press.
7. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003;34:537-543.
8. Baird AE, Benfield A, Schlaug G, Siewert B, Lovblad KO, Edelman RR, Warach S. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol. 1997;41:581-589.
9. Karonen JO, Vanninen RL, Liu Y, Ostergraad L, Kuikka JT, Nuutinen J, Vanninen EJ, Partanen PL, Vainio PA, Korhonen K, Perkiö J, Roivainen R, Silvenius J, Aronen HJ. Combined diffusion and perfusion MRI with correlation to single-photon emission CT in acute ischemic stroke. Ischemic penumbra predicts infarct growth. Stroke. 1999;30:1583-1590.
10. Warach S. Thrombolysis in stroke beyond three hours: targeting patients with diffusion and perfusion MRI. Ann Neurol. 2002;51:11-13.
11. Chalela JA, Kang D-W, Luby M, Ezzeddine M, Latour LL, Todd JW, Dunn B, Warach S. Ultra-early MRI findings in patients receiving tissue plasminogen activator predict clinical outcome: new insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55:105-112.
12. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28: 2109-2118.
13. Larrue V, von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS). Stroke. 2001;31: 438-441.